Microcide Pharmaceuticals, Inc.

Anacor Pharmaceuticals, Inc.

Essential Therapeutics, Inc.

Wyeth Holdings Corporation

Iconix Pharmaceuticals, Inc.

Limerick Biopharma

Ving J Lee

Scott J Hecker

Zhijia J Zhang

In-Seop Cho

Tomasz W Glinka

Roger Leger

Dongxu Sun

Yong-Kang Zhang

Tsutomu Akama

Stephen J Benkovic

Kirk R Maples

Stephen J Baker

Molly B Schmid

Francois Malouin

Bret Benton

Patrick K Martin

Vittorio A Sauro

Rajeshwar Singh

Suzanne Chamberland

Burton G Christensen

Jacob J Plattner

Carolyn Bellinger-Kawahara

Thomas Eric Renau

May Lee

Joseph J Hlavka

Phaik-Eng Sum

Yakov Gluzman

Zhuoyi Su

Adma A Ross

Zhixiang Yang

Miles She

Chetan Pandit

William John Watkins

Aesop Cho

Kiyoshi Nakayama

Constantine G Boojamra

Stuart Tugendreich

Edward Perkins

Toshiharu Ohta

Masami Ohtsuka

Joaquim Trias

David Morgans

Kurt Jarnigan

Roger L&eacute;ger

R&eacute;my C Lemoine

Wendye Robbins

Yohei Ishida

Rajesjwar Singh

Richard Fronko

Tomaz W Glinka

Trevor Calkins

Compositions and methods of use of boron derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by fungi, yeast, bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.

Hydrolytically-resistant boron-containing therapeutics and methods of use

Compositions and methods of use of borole derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.

The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents.

Phosphorylated pyrone analogs and methods

The structure and preparation of antibiotics incorporating borinic acid complexes are disclosed, especially hydroxyquinoline, imidazole and picolinic acid derivatives, along with compositions of these antibiotics and methods of using the antibiotics and compositions as bactericidal and fungicidal agents as well as therapeutic agents for the treatment of diseases caused by bacteria and fungi.

Antibiotics containing borinic acid complexes and methods of use

The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formulawherein R, X, Rand Rare defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.

7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines

The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.

Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof

Modulators of Rho C activity

This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.

Methods of screening for compounds active on staphylococcus aureus target genes

Methods of screening for compounds active on Staphylococcus aureus target genes

The present invention relates to dihydro derivatives of the uridyl peptide antibiotics mureidomycin, pacidimycin and napsamycin which have antibiotic activity against a number of bacterial strains including strains resistant to current therapeutic antibiotics.

Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use

Compounds of the invention have the structure D&mdash;L&mdash;A*, where L is a linking moiety that maintains D and A in a configuration compatible with FRET, D is a fluorescent donor moiety capable of causing an acceptor moiety to fluoresce by FRET, and A* is a fluorescent acceptor moiety capable of accepting energy from the donor moiety by FRET and fluorescing only after cleavage of one or more labile groups to provide acceptor A. These compounds are useful as fluorescent substrates for detection of enzymes in vivo.

Hydrolytic enzyme substrates and assay method

Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

Peptidomimetic efflux pump inhibitors

Growing community of inventors

Los Altos, CA, United States of America

Ving J Lee